Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:3:199-210.
doi: 10.2147/opth.s4806. Epub 2009 Jun 2.

Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution

Hyung Cho  1 , Kenneth J Wolf, Eric J Wolf
Affiliations

Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution

Hyung Cho et al. Clin Ophthalmol. 2009.

Abstract

Recently, several new ophthalmic NSAID products have been introduced for commercial use in the United States. The purpose of this review is to briefly overview the ophthalmic NSAIDs currently in use and to discuss the management of postoperative ocular inflammation and pain following cataract surgery with a particular focus on bromfenac ophthalmic solution 0.09%. Bromfenac ophthalmic solution 0.09% is indicated for the reduction of ocular pain and inflammation following cataract surgery. Studies have shown that bromfenac ophthalmic solution 0.09% has equivalent efficacy to the other topical NSAIDs in reducing postsurgical inflammation and controlling pain. The unique chemical structure of bromfenac makes it both a potent inhibitor of the COX-2 enzyme and a highly lipophilic molecule that rapidly penetrates to produce early and sustained drug levels in all ocular tissues. Clinically, these pharmacokinetic features are manifested in a rapid reduction of postsurgical inflammation and pain with bid dosing. Bromfenac ophthalmic solution 0.09% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids.

Keywords: bromfenac; ocular inflammation; ophthalmic NSAIDs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prostaglandin and thromboxan biosynthesis. After FitzGerald and Patrono 2001. Abbreviations: COX, cyclooxygenase; coxibs, COX-2 inhibitors; PG, prostaglandin; TxA2, thromboxane A2; NSAID, nonsteroidal anti-inflammatory drug; ASA, aspirin.
Figure 2
Figure 2
Chemical structure of bromfenac.
Figure 3
Figure 3
Deamination of nepafenac to the active compound amfenac.
See this image and copyright information in PMC

References

    1. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical Ocular Delivery of NSAIDs. AAPS J. 2008 Apr 25; - PMC - PubMed
    1. McColgin AZ, Heier JS. Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2000;11:3–6. - PubMed
    1. Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4% Expert Opin Pharmacother. 2006;7(1):99–107. - PubMed
    1. Chang JH, Chung H. Non-steroidal anti-inflammatory drug and endotoxin induced unveitis. Korean J Ophthalmol. 1993;7:35–42. - PubMed
    1. Polansky JR, Weinreb RN. Steroids as anti-inflammatory agents. In: Sears ML, editor. Pharmacology of the Eye. Springer-Verlag; New York: 1984. pp. 460–538.